Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8539484 | 0.98 | ALDH1A1 (0.58) | ALDH1A1TSHRHTTHPGDMAOB | |
| SCHEMBL77922 | 0.90 | ALDH1A1 (0.62) | ALDH1A1TSHRHTTHPGDMAOB | |
| SCHEMBL12086376 | 0.84 | ALDH1A1 (0.55) | ALDH1A1TSHRHTTHPGDMAOB | |
| SCHEMBL38655942 | 0.84 | ALDH1A1 (0.65) | ALDH1A1TSHRHTTHPGDMAOB | |
| SCHEMBL28385453 | 0.84 | ALDH1A1 (0.55) | ALDH1A1TSHRHTTHPGDMAOB | |
| SCHEMBL3157228 | 0.84 | ALDH1A1 (0.55) | ALDH1A1TSHRHTTHPGDMAOB | |
| SCHEMBL3937015 | 0.84 | ALDH1A1 (0.55) | ALDH1A1TSHRHTTHPGDMAOB | |
| SCHEMBL2354939 | 0.84 | ALDH1A1 (0.59) | ALDH1A1TSHRHTTHPGDMAOB | |
| SCHEMBL7027259 | 0.84 | ALDH1A1 (0.55) | ALDH1A1TSHRHTTHPGDMAOB | |
| SCHEMBL3937020 | 0.84 | ALDH1A1 (0.55) | ALDH1A1TSHRHTTHPGDMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230049294-A1 | STEREOSELECTIVE PROCESS OF MANUFACTURE OF PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2023-02-16 | — | — | US | claimed |
| WO-2021216722-A1 | STEREOSELECTIVE PROCESS OF MANUFACTURE OF PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2021-10-28 | — | — | WO | claimed |
| EP-3494996-B1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | AGENSYS INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12551499-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260034234-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260000604-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | AGENSYS, INC. (US) | 2026-01-01 | — | — | US | disclosed |
| US-12496353-B2 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway | SEAGEN INC. (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4604951-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | AMIRA THERAPEUTICS, S.L. (ES) | 2025-08-27 | — | — | EP | disclosed |
| CN-113412268-B | Modified nucleoside at 5' -position and nucleotide using the same | 国立大学法人大阪大学 | 2025-06-17 | — | — | CN | disclosed |
| CN-113784721-B | High activity compounds against COVID-19 | 阿堤亚制药公司 | 2025-06-13 | — | — | CN | disclosed |
| WO-2025095052-A1 | CARBOCYCLIC NUCLEOSIDE-CONTAINING OLIGONUCLEOTIDE | リードファーマ株式会社 | 2025-05-08 | — | — | WO | disclosed |
| WO-2008153278-A1 | PHOSPHAZENE HYDROGELS WITH CHEMICAL CORSS -LINK, PREPARATION METHOD THEREOF AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2008-12-18 | — | — | WO | disclosed |
| EP-1957644-A2 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | Nuevolution A/S (DK) | 2008-08-20 | — | — | EP | disclosed |
| EP-1896480-A1 | CRIPOWELLINS AND SYNTHETIC DERIVATIVES THEREOF USED AS MEDICAMENTS | Bayer CropScience Aktiengesellschaft (DE) | 2008-03-12 | — | — | EP | disclosed |
| WO-2008019784-A2 | AVERMECTIN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007062664-A2 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2007-06-07 | — | — | WO | disclosed |
| WO-2006136309-A1 | CRIPOWELLINS AND SYNTHETIC DERIVATIVES THEREOF USED AS MEDICAMENTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | WO | disclosed |
| EP-1412346-B1 | METHOD FOR PRODUCING NOVEL SPINOSYN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2005-03-09 | — | — | EP | disclosed |
| EP-1412346-A1 | METHOD FOR PRODUCING NOVEL SPINOSYN DERIVATIVES | Bayer CropScience AG (DE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003010155-A1 | METHOD FOR PRODUCING NOVEL SPINOSYN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12496353-B2 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway | MTOR, RICTOR, PIK3R5 | ALDH1A1 3563/4885TSHR 2706/4885HTT 2925/4885 |
| US-20260000604-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | CD44, CA12, H1-10 | ALDH1A1 3280/4885TSHR 2385/4885HTT 1543/4885 |
| US-12551499-B2 | Highly active compounds against COVID-19 | PNP, SLC29A2, MTAP | ALDH1A1 1808/4885TSHR 3265/4885HTT 3318/4885 |
| US-20230049294-A1 | STEREOSELECTIVE PROCESS OF MANUFACTURE OF PURINE PHOSPHORAMIDATES | NUDT1, PNP, ITPA | ALDH1A1 1210/4885TSHR 3591/4885HTT 2034/4885 |
| US-20260034234-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | IGSF11, ARID2, DYNLL2 | ALDH1A1 1803/4885TSHR 3069/4885HTT 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.